Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.5%
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.5%
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating)'s share price shot up 3.5% on Thursday . The stock traded as high as $14.67 and last traded at $14.67. 8,711 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 868,368 shares. The stock had previously closed at $14.17.
納斯達克股價週四大漲3.5%,盤中一度漲至14.67美元,尾盤報14.67美元。午盤,共有8,711股股票易手,較868,368股的平均成交量下跌99%。該股此前收盤報14.17美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several brokerages have recently weighed in on ARQT. Jonestrading restated a "buy" rating and issued a $54.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, September 22nd. Morgan Stanley upped their price objective on Arcutis Biotherapeutics from $49.00 to $51.00 and gave the company an "overweight" rating in a report on Tuesday, December 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $51.60.
幾家券商最近也加入了ARQT的行列。Jones Trading在9月22日星期四的一份報告中重申了“買入”評級,並對Arcutis BioTreateutics的股票發佈了54.00美元的目標價。12月13日,週二,摩根士丹利在一份報告中將Arcutis BioTreatetics的目標價從49美元上調至51美元,並給予該公司“增持”評級。根據MarketBeat.com的數據,六位投資分析師對該股的評級為買入,該公司目前的平均評級為買入,共識目標價為51.60美元。
Arcutis Biotherapeutics Stock Up 6.3 %
Arcutis BioTreateutics股價上漲6.3%
The business has a 50-day moving average price of $16.18 and a 200-day moving average price of $19.55. The company has a market capitalization of $917.58 million, a price-to-earnings ratio of -2.41 and a beta of 0.49. The company has a quick ratio of 13.27, a current ratio of 13.39 and a debt-to-equity ratio of 0.73.
該業務的50日移動均線價格為16.18美元,200日移動均線價格為19.55美元。該公司市值為9.1758億美元,市盈率為-2.41倍,貝塔係數為0.49。該公司的速動比率為13.27,流動比率為13.39,債務權益比率為0.73。
Insider Activity at Arcutis Biotherapeutics
Arcutis BioTreateutics的內部活動
In related news, Director Howard G. Welgus sold 8,500 shares of the company's stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $13.72, for a total transaction of $116,620.00. Following the transaction, the director now directly owns 165,825 shares of the company's stock, valued at $2,275,119. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Howard G. Welgus sold 8,500 shares of the company's stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $13.72, for a total transaction of $116,620.00. Following the transaction, the director now directly owns 165,825 shares of the company's stock, valued at $2,275,119. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Masaru Matsuda sold 1,720 shares of the company's stock in a transaction on Monday, November 21st. The shares were sold at an average price of $18.19, for a total value of $31,286.80. Following the transaction, the insider now directly owns 19,535 shares in the company, valued at $355,341.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,695 shares of company stock valued at $205,107. Company insiders own 23.00% of the company's stock.
在相關新聞中,董事霍華德·G·韋爾格斯在1月17日(星期二)的一次交易中出售了8,500股該公司股票。該股以13.72美元的平均價格出售,總成交金額為116,620.00美元。交易完成後,董事現在直接持有該公司股票165,825股,價值2275,119美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過這個環節。在相關新聞中,董事霍華德·G·韋爾格斯在1月17日(星期二)的一次交易中出售了8,500股該公司股票。該股以13.72美元的平均價格出售,總成交金額為116,620.00美元。交易完成後,董事現在直接持有該公司股票165,825股,價值2275,119美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過這個環節。此外,內部人士松田正郎在11月21日星期一的一次交易中出售了1,720股該公司股票。這些股票的平均價格為18.19美元,總價值為31,286.80美元。交易完成後,這位內部人士現在直接擁有該公司19,535股,價值355,341.65美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士賣出了13,695股公司股票,價值205,107美元。公司內部人士持有該公司23.00%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Several hedge funds have recently bought and sold shares of ARQT. Swiss National Bank increased its position in Arcutis Biotherapeutics by 7.8% in the 1st quarter. Swiss National Bank now owns 59,500 shares of the company's stock worth $1,146,000 after purchasing an additional 4,300 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Arcutis Biotherapeutics by 20.8% during the 1st quarter. JPMorgan Chase & Co. now owns 27,022 shares of the company's stock worth $520,000 after acquiring an additional 4,646 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Arcutis Biotherapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 16,718 shares of the company's stock valued at $322,000 after purchasing an additional 6,170 shares during the period. Dimensional Fund Advisors LP boosted its stake in Arcutis Biotherapeutics by 83.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 227,383 shares of the company's stock valued at $4,378,000 after purchasing an additional 103,477 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Arcutis Biotherapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,531,098 shares of the company's stock valued at $29,489,000 after purchasing an additional 16,770 shares during the period.
幾家對衝基金最近買賣了ARQT的股票。瑞士國家銀行在第一季度將其在Arcutis BioTreateutics的頭寸增加了7.8%。瑞士國家銀行現在持有59,500股該公司股票,價值1,146,000美元,在上個季度又購買了4,300股。摩根大通在第一季度增持了Arcutis BioTreateutics的股份20.8%。摩根大通在上個季度增持了4,646股後,目前持有27,022股該公司股票,價值52萬美元。大都會人壽投資管理公司在第一季度將其在Arcutis BioTreateutics的持股增加了58.5%。大都會人壽投資管理公司目前持有該公司16,718股股票,價值322,000美元,在此期間又購買了6,170股。Dimension Fund Advisors LP在第一季度將其在Arcutis BioTreateutics的持股增加了83.5%。Dimension Fund Advisors LP現在擁有227,383股該公司的股票,價值4,378,000美元,在此期間又購買了103,477股。最後,先鋒集團(Vanguard Group Inc.)在第一季度將其在Arcutis BioTreateutics的持股增加了1.1%。先鋒集團目前持有1,531,098股該公司股票,價值29,489,000美元,在此期間又購買了16,770股。
About Arcutis Biotherapeutics
關於Arcutis生物療法
(Get Rating)
(獲取評級)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Arcutis BioTreateutics,Inc.是一家生物製藥公司,專注於皮膚病治療方法的開發和商業化。它的主要候選產品是ARQ-151,這是一種外用羅氟司特乳膏,已經完成了治療斑塊型牛皮癬和特應性皮炎的第三階段臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Arcutis Biotherapeutics (ARQT)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
- 免費獲取StockNews.com關於弓狀生物療法(ARQT)的研究報告
- 愛彼迎的漲幅是否會像分析師預測的那樣達到38%?
- 特斯拉汽車降價是否意味着特斯拉股票也會降價?
- 微軟的裁員標誌着其他科技公司的裁員?
- 快速購買Fastenal的原因不止一個
- 3只有吸引力的防禦性股票,股息為3%
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Arcutis BioTreatetics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Arcutis BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。